Analysts expect Cyclerion Therapeutics, Inc. to report revenue of 161,913.78 for Q3 22, against a range of 148,464.09 to 175,363.47. The most recent reported quarter, Q2 22, came in at 306,000.00, a 9.8% miss against the 339,063.46 consensus.
| Metric | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 711,000.00 | 306,000.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | 613,568.34 | 371,911.25 | 175,363.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103,496.59 | 185,812.77 | |||||||||||
| Low Estimate | 551,793.66 | 306,215.67 | 148,464.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 91,756.41 | 162,826.63 | |||||||||||
| Consensus Estimate | 582,681.00 | 339,063.46 | 161,913.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 97,626.50 | 174,319.70 |
Analysts expect Cyclerion Therapeutics, Inc. to report earnings per share of -6.07 for Q3 22, against a range of -6.60 to -5.54. The most recent reported quarter, Q2 22, came in at -6.20, a 9.5% miss against the -5.66 consensus.
| Metric | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -6.20 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -5.45 | -5.54 | -5.41 | -6.00 | -5.43 | -5.54 | -6.93 | -0.34 | -0.31 | |||||||||||
| Low Estimate | -5.87 | -6.60 | -6.59 | -6.42 | -5.99 | -6.38 | -8.45 | -0.40 | -0.35 | |||||||||||
| Consensus Estimate | -5.66 | -6.07 | -6.00 | -6.21 | -5.71 | -5.96 | -7.69 | -0.37 | -0.33 |